Organ transplant recipients have a 200-fold increased incidence of keratinocyte carcinoma compared with immunocompetent individuals, and cSCC accounts for 80% of skin cancers in those recipients.
Exa-cel earned its second FDA approval. The one-time therapy, which has a list price of $2.2 million in the United States, should be available for patients early this year.
"The findings suggest that early detection and management of vitiligo lesions can be improved by estimating the likelihood of its development in transplant recipients."